Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by D. Bogle
Extended Dose Ipilimumab With a Peptide Vaccine: Immune Correlates Associated With Clinical Benefit in Patients With Resected High-Risk Stage IIIc/IV Melanoma
Clinical Cancer Research
Cancer Research
Oncology
Related publications
High-Dose Glucocorticoids for the Treatment of Ipilimumab-Induced Hypophysitis Is Associated With Reduced Survival in Patients With Melanoma
Cancer
Cancer Research
Oncology
Vaccine-Specific Immune Responses Correlate With Clinical Benefit
Cancer Discovery
Oncology
Fatal Myocarditis and Rhabdomyositis in a Patient With Stage IV Melanoma Treated With Combined Ipilimumab and Nivolumab
Current Oncology
Oncology
Antibody Response to Melanoma Helper-Peptide Vaccine Correlates With Survival
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Q-TWiST Analysis Comparing Ipilimumab/Dacarbazine vs Placebo/Dacarbazine for Patients With Stage III/IV Melanoma
British Journal of Cancer
Cancer Research
Oncology
Bevacizumab Plus Ipilimumab in Patients With Metastatic Melanoma
Cancer immunology research
Cancer Research
Immunology
Association of First-In-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma
JAMA Oncology
Cancer Research
Oncology
Prolonged Benefit From Ipilimumab Correlates With Improved Outcomes From Subsequent Pembrolizumab
Cancer immunology research
Cancer Research
Immunology
Adjuvant Ipilimumab in High-Risk Uveal Melanoma
Cancers
Cancer Research
Oncology
